Immunovant Inc. (IMVT) Next Earnings Date & Options-Implied ±6.8% Move
Immunovant Inc. (IMVT) carries a Roarable Rating of C (Hold) with 63/100 RQD Confidence. The underlying business is intact, so current owners don’t need to panic-sell—but mixed big-money flow or rich pricing means new buyers can afford to wait for either a pullback or a B-or-higher upgrade.
Options-Implied Post-Earnings ±6.8% Bell Curve
Will IMVT Beat & Rip or Miss Next Quarter?
Trailing EPS: $-2.45 • YoY Revenue Growth: 9.9%
Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence
| Period | Filed | Revenue | Net Profit | Free Cash Flow | Gross Margin |
|---|---|---|---|---|---|
| FY 2025 | 2026-03-31 | $0 | -$505.6M | -$407.3M | 41% |
| FY 2024 | 2025-03-31 | $0 | -$413.8M | -$376.6M | 41% |
| FY 2023 | 2024-03-31 | $0 | -$259.3M | -$214.2M | 41% |
Whale Flow & Momentum Playbook: Trading IMVT & AI Leaders Without Chasing Tops
- ✓Exact institutional whale strikes & implied earnings range on IMVT this week
- ✓How active traders scale setups using funded prop-firm accounts instead of risking savings
- ✓Free bonus: instant RQD Rating Flip alerts on all tracked momentum leaders
IMVT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +9.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on IMVT today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for IMVT. Explore sector supply chains on /butterfly.
IMVT Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhen is IMVT's next earnings date?
Based on SEC filing cadence, Immunovant Inc. (IMVT)'s next quarterly earnings window is estimated around Dec 29, 2026.
How much is IMVT stock expected to move on earnings?
Options markets currently imply a ±6.8% post-earnings move for IMVT, projecting a trading range between $27.62 and $31.66.